Your weekly recap of news and analysis from the psychedelic sector.
Psychedelic Bulletin: MindMed Raises $92.1m; Mount Sinai Establishes Psychedelics Centre; More Legal Exemptions for Psilocybin in Canada
This Week: MindMed closed a $92.1m raise, COMPASS Pathways and Mount Sinai established centres dedicated to psychedelic therapy and research, more Canadians receive legal exemptions for psilocybin-assisted therapy…
Psychedelic Bulletin: First Psychedelic ETF Set to Launch; Beckley Psytech Raises £14m; Reviewing the Psychedelic Renaissance in 2020
This Week: Among coverage of a number of raises, and the first psychedelic ETF, we round off a remarkable year for psychedelics, and the world more broadly.
Psychedelic Bulletin: MindMed Raises $34.5m; Tryp Goes Public; What Health Canada’s Latest Amendment Means for Psychedelics
This Week: Canada to consider allowing psychedelic therapy under Special Access Program; MindMed raises $34.5m, announces $80m offering; Tryp goes public.
This week: 17 Canadian healthcare professionals receive approval to use psilocybin; UK regulators approve DMT for depression trial; capital continues to flow into the psychedelic space.
Psychedelic Bulletin: Numinus & MAPS Seek Approval for MDMA Trial in Canada; Psychedelic Companies Commission Research into Psilocybin, DMT, LSD
This week: MAPS and Numinus announce plans for a compassionate access trial of MDMA for PTSD in Canada; more psychedelics companies contract studies; mainstream media covers the space.
Psychedelic Bulletin: ATAI Raises $125m, MindMed CAD $25m; BBC Programme to Follow Psychedelics Trial
This week: ATAI Life Sciences has raised $125m in their Series C round, MindMed announced a bought deal worth $25m, and we learned the BBC is producing a documentary following a Psychedelics trial.